Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Zussman 2020 J Autoimmun"

From Bioblast
 
Line 1: Line 1:
{{Publication
{{Publication
|title=Zussman R, Xu LY, Damani T, Groom KM, Chen Q, Seers B, Viall CA, Chamley LW, Hickey A (2020) Antiphospholipid antibodies can specifically target placental mitochondria and induce ROS production. J Autoimmun [Epub ahead of print].
|title=Zussman R, Xu LY, Damani T, Groom KM, Chen Q, Seers B, Viall CA, Chamley LW, Hickey A (2020) Antiphospholipid antibodies can specifically target placental mitochondria and induce ROS production. J Autoimmun 111:102437.
|info=[https://www.ncbi.nlm.nih.gov/pubmed/32224053 PMID: 32224053]
|info=[https://www.ncbi.nlm.nih.gov/pubmed/32224053 PMID: 32224053]
|authors=Zussman R, Xu Lance Y, Damani T, Groom KM, Chen Qi, Seers B, Viall CA, Chamley LW, Hickey A
|authors=Zussman R, Xu Lance Y, Damani T, Groom KM, Chen Qi, Seers B, Viall CA, Chamley LW, Hickey A

Latest revision as of 16:55, 1 July 2020

Publications in the MiPMap
Zussman R, Xu LY, Damani T, Groom KM, Chen Q, Seers B, Viall CA, Chamley LW, Hickey A (2020) Antiphospholipid antibodies can specifically target placental mitochondria and induce ROS production. J Autoimmun 111:102437.

» PMID: 32224053

Zussman R, Xu Lance Y, Damani T, Groom KM, Chen Qi, Seers B, Viall CA, Chamley LW, Hickey A (2020) J Autoimmun

Abstract: Women with antiphospholipid antibodies (aPL) have increased risks of pregnancy complications, including a ten-fold increased risk of preeclampsia, which is potentially triggered by the release of placental toxins. Previously, aPL were shown to enter the outer layer of the placenta, the syncytiotrophoblast, associate with mitochondria, and alter mitochondrial function. We hypothesised that aPL may also increase mitochondrial reactive oxygen species (ROS) production, leading to cellular dysfunction and release of toxins. First trimester placental explants were incubated with monoclonal aPL, ID2 and IIC5 (25, 50, and 100 μg/mL), for 3 h at 37 °C and ROS production followed using CellROX Deep Red. In addition, the candidate treatment compounds chloroquine, melatonin, and Mito-Q were tested at therapeutic concentrations for their ability to prevent ROS production. Mitochondria isolated from term placentae were incubated with fluorescently-labelled ID2, IIC5, or control IgG antibodies (2.5, 5, 10, or 20 μg/mL) for 30 min, and mitochondria with bound antibodies were quantified using flow cytometry. In addition, respirometry coupled with fluorimetry was used to interrogate explant mitochondrial respiration and ROS production following incubation with 25, 50, or 100 μg/mL ID2, IIC5, or control IgG for 3 h at 37 °C. ID2 increased explant ROS production in a manner that was completely prevented by the endocytosis inhibitor chloroquine, and partially prevented by the antioxidants melatonin and Mito-Q. Both ID2 and IIC5 displayed a greater ability to bind isolated mitochondria than control antibodies, and increased ROS production attributable to the mitochondrial enzyme glycerol 3-phosphate dehydrogenase (mGPDH). Our evidence supports the hypothesis that aPL interact with syncytiotrophoblast mitochondria, likely via the binding of cardiolipin and β2 glycoprotein I in mitochondrial membranes, and induce ROS production which contributes to overall oxidative stress and placental dysfunction.

Copyright © 2020 Elsevier Ltd. All rights reserved. Keywords: Antioxidant, Antiphospholipid antibodies, Chloroquine, Mitochondria, Placenta, Reactive oxygen species Bioblast editor: Plangger M O2k-Network Lab: NZ Auckland Hickey AJ


Labels: MiParea: Respiration, Pharmacology;toxicology 

Stress:Oxidative stress;RONS  Organism: Human  Tissue;cell: Genital  Preparation: Permeabilized tissue 


Coupling state: LEAK, ET  Pathway: N, S, Gp, CIV, NS, ROX  HRR: Oxygraph-2k, O2k-Fluorometer 

2020-04, AmR